Shana M. Coley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shana M. Coley has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Anjali Saqi
Department of Pathology and Cell Biology Columbia University Irving Medical Center New York NY USA
6 shared publications - Brian S. Henick
Columbia University Irving Medical Center, New York, NY
6 shared publications - Catherine A. Shu
Columbia University Irving Medical Center, New York, NY
6 shared publications - Jianhua Hu
Department of Biostatistics, Columbia University
6 shared publications - Naiyer A. Rizvi
Columbia University Irving Medical Center, New York, New York
6 shared publications - Peter H. Wang
Department of Microbiology and Immunology, Columbia University Irving Medical Center; New York, NY, USA
6 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Elsevier in SSRN Electronic Journal
Tolerant Human T Cells Developing in a Porcine Thymic Graft Following Pig-to-Living Human Thymokidney Xenotransplantation
Xenotransplantation represents a promising strategy to address the organ shortage. Immune tolerance has been achieved with thymic xenotransplantation in preclinical models offering the possibility of reducing or eliminating immunosuppression. Here we report on the outcome of a composite α1,3-galactosyltransferase knockout (GGTA1KO) porcine thymus plus kidney (thymokidney) xenotransplant in a 54-year-old woman with congestive heart failure and dialysis-dependent renal failure who also received a left ventricular assist device (LVAD) implant under an FDA expanded access, single patient IND. Early peripheral blood T-cell recovery after depletion was characterized by naïve recent thymic emigrants (RTEs). T cell clones detected post-transplant and not in pre-transplant populations did not infiltrate the kidney extensively and peripheral blood mixed lymphocyte reaction (MLR) assays demonstrated evolving donor-specific hyporesponsiveness. Collectively, these data indicate that human T cells developed de novo in the porcine thymus and were tolerant of the source pig antigens.
- 30 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTolerant Human T Cells Developing in a Porcine Thymic Graft Following Pig-to-Living Human Thymokidney Xenotransplantation
Xenotransplantation represents a promising strategy to address the organ shortage. Immune tolerance has been achieved with thymic xenotransplantation in preclinical models offering the possibility of reducing or eliminating immunosuppression. Here we report on the outcome of a composite α1,3-galactosyltransferase knockout (GGTA1KO) porcine thymus plus kidney (thymokidney) xenotransplant in a 54-year-old woman with congestive heart failure and dialysis-dependent renal failure who also received a left ventricular assist device (LVAD) implant under an FDA expanded access, single patient IND. Early peripheral blood T-cell recovery after depletion was characterized by naïve recent thymic emigrants (RTEs). T cell clones detected post-transplant and not in pre-transplant populations did not infiltrate the kidney extensively and peripheral blood mixed lymphocyte reaction (MLR) assays demonstrated evolving donor-specific hyporesponsiveness. Collectively, these data indicate that human T cells developed de novo in the porcine thymus and were tolerant of the source pig antigens.
- Open Access
- 23 July 2026
- Published by Wolters Kluwer Health in Transplantation
Molecular Classification Predicts Clinical Outcomes of Kidney Transplant Recipients With Microvascular Inflammation, Donor-specific Antibodies-negative and C4d-negative
Background.: Microvascular inflammation (MVI), donor-specific antibodies (DSAs)-negative and C4d-negative, was recently defined as a distinct phenotype by Banff 2022 and has been associated with adverse clinical outcomes. We have developed a model for rejection-related molecular classification of renal allograft biopsies using gene expression profiling of formalin-fixed paraffin-embedded renal biopsy tissue and evaluated its performance in patients with MVI. Methods.: Using this updated gene expression profiling-based multiclass model, we evaluated 138 biopsy specimens obtained from a large US transplant center, which included 42 biopsies diagnosed as MVI, DSA-negative, and C4d-negative. Clinical outcomes of patients in this MVI biopsy group were analyzed in relation to their molecular classifications. Results.: The molecular rejection classifications exhibited robust concordance with histology diagnoses of no rejection, antibody-mediated rejection, and T-cell–mediated rejection in this independent cohort, with concordance rates varying in each group from 85% to 93%. The molecular classification also showed a significant association with differential renal function and graft survival in the MVI, DSA-negative, and C4d-negative group. Conclusions.: Our model demonstrates significant molecular differentiation among antibody-mediated rejection, T-cell–mediated rejection, and no rejection. In addition, our model classified MVI, DSA-negative, and C4d-negative samples into molecular subgroups associated with divergent clinical outcomes.
- 23 July 2026
- Published by Wolters Kluwer Health in Transplantation
Open AccessMolecular Classification Predicts Clinical Outcomes of Kidney Transplant Recipients With Microvascular Inflammation, Donor-specific Antibodies-negative and C4d-negative
Background.: Microvascular inflammation (MVI), donor-specific antibodies (DSAs)-negative and C4d-negative, was recently defined as a distinct phenotype by Banff 2022 and has been associated with adverse clinical outcomes. We have developed a model for rejection-related molecular classification of renal allograft biopsies using gene expression profiling of formalin-fixed paraffin-embedded renal biopsy tissue and evaluated its performance in patients with MVI. Methods.: Using this updated gene expression profiling-based multiclass model, we evaluated 138 biopsy specimens obtained from a large US transplant center, which included 42 biopsies diagnosed as MVI, DSA-negative, and C4d-negative. Clinical outcomes of patients in this MVI biopsy group were analyzed in relation to their molecular classifications. Results.: The molecular rejection classifications exhibited robust concordance with histology diagnoses of no rejection, antibody-mediated rejection, and T-cell–mediated rejection in this independent cohort, with concordance rates varying in each group from 85% to 93%. The molecular classification also showed a significant association with differential renal function and graft survival in the MVI, DSA-negative, and C4d-negative group. Conclusions.: Our model demonstrates significant molecular differentiation among antibody-mediated rejection, T-cell–mediated rejection, and no rejection. In addition, our model classified MVI, DSA-negative, and C4d-negative samples into molecular subgroups associated with divergent clinical outcomes.
- Open Access
- 3 July 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (8) , 1-14
Mechanosensing by T cells promotes a tissue-resident memory transcriptional program
Cell migration and strategic positioning within tissues is critical for the rapid mobilization of a T cell response. T cells must remain motile in both lymphoid and nonlymphoid tissues, which vary widely in mechanical properties such as stiffness. Here we showed that activated T cells sensed mechanical cues and responded with changes in cell morphology, nuclear envelope composition and initiation of DNA repair to protect their genomic material from force-mediated damage. Increased mechanical input also drove the transcriptional reprogramming of activated T cells, including changes in many of the core genes shared by tissue-resident memory T cells across diverse tissues, by modulating the expression of the tissue-resident memory T cell-associated transcription factors Klf2, Runx3 and Hic1. Thus, mechanosensing by activated T cells impacted T cell fate, promoting a transcriptional program associated with tissue residency.
- 3 July 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (8) , 1-14
Open AccessMechanosensing by T cells promotes a tissue-resident memory transcriptional program
Cell migration and strategic positioning within tissues is critical for the rapid mobilization of a T cell response. T cells must remain motile in both lymphoid and nonlymphoid tissues, which vary widely in mechanical properties such as stiffness. Here we showed that activated T cells sensed mechanical cues and responded with changes in cell morphology, nuclear envelope composition and initiation of DNA repair to protect their genomic material from force-mediated damage. Increased mechanical input also drove the transcriptional reprogramming of activated T cells, including changes in many of the core genes shared by tissue-resident memory T cells across diverse tissues, by modulating the expression of the tissue-resident memory T cell-associated transcription factors Klf2, Runx3 and Hic1. Thus, mechanosensing by activated T cells impacted T cell fate, promoting a transcriptional program associated with tissue residency.
- Open Access
- 14 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (7) , 1561-1576
Pathologic Evaluation of Pig Kidney and Heart Xenografts: 2024 Recommendations from the Banff Xenotransplantation Pathology Working Group
- 14 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (7) , 1561-1576
Open AccessPathologic Evaluation of Pig Kidney and Heart Xenografts: 2024 Recommendations from the Banff Xenotransplantation Pathology Working Group
- Top Cited PapersOpen Access
- 5 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 922-936
The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning
- 5 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 922-936
Top Cited PapersOpen AccessThe Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.
- Open Access
- 12 December 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 104 (3) , 100304
Development and Validation of a Multiclass Model Defining Molecular Archetypes of Kidney Transplant Rejection: A Large Cohort Study of the Banff Human Organ Transplant Gene Expression Panel
- 12 December 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 104 (3) , 100304
Open AccessDevelopment and Validation of a Multiclass Model Defining Molecular Archetypes of Kidney Transplant Rejection: A Large Cohort Study of the Banff Human Organ Transplant Gene Expression Panel
- Top Cited PapersOpen Access
- 4 November 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 350-361
The Banff 2022 Kidney Meeting Work Plan: Data-driven refinement of the Banff Classification for renal allografts
- 4 November 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 350-361
Top Cited PapersOpen AccessThe Banff 2022 Kidney Meeting Work Plan: Data-driven refinement of the Banff Classification for renal allografts